Cell MedX Corp. (CMXC)
USD 0.43
(0.0%)
USD 0.43
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 46.12 Thousand USD | -55.34% |
| 2023 | 103.27 Thousand USD | 149.78% |
| 2022 | 41.34 Thousand USD | -20.86% |
| 2021 | 52.24 Thousand USD | -67.18% |
| 2020 | 159.17 Thousand USD | -16.46% |
| 2019 | 190.54 Thousand USD | 321.0% |
| 2018 | 45.25 Thousand USD | -84.59% |
| 2017 | 293.72 Thousand USD | 9.22% |
| 2016 | 268.92 Thousand USD | 477.54% |
| 2015 | 46.56 Thousand USD | 3777.1% |
| 2014 | 1201.00 USD | -89.06% |
| 2013 | 10.97 Thousand USD | -53.51% |
| 2012 | 23.61 Thousand USD | 138811.76% |
| 2011 | 17.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 62.32 Thousand USD | -39.65% |
| 2024 FY | 46.12 Thousand USD | -55.34% |
| 2024 Q4 | 46.12 Thousand USD | -43.7% |
| 2024 Q3 | 81.91 Thousand USD | 257.99% |
| 2024 Q2 | 22.88 Thousand USD | -63.28% |
| 2023 Q2 | 24.02 Thousand USD | -15.94% |
| 2023 Q3 | 13.89 Thousand USD | -42.15% |
| 2023 Q1 | 28.57 Thousand USD | -30.88% |
| 2023 FY | 103.27 Thousand USD | 149.78% |
| 2023 Q4 | 103.27 Thousand USD | 643.16% |
| 2022 Q3 | 54.9 Thousand USD | -24.35% |
| 2022 Q1 | 101.89 Thousand USD | 95.05% |
| 2022 Q2 | 72.57 Thousand USD | -28.78% |
| 2022 FY | 41.34 Thousand USD | -20.86% |
| 2022 Q4 | 41.34 Thousand USD | -24.69% |
| 2021 Q3 | 100.04 Thousand USD | 2.38% |
| 2021 FY | 52.24 Thousand USD | -67.18% |
| 2021 Q4 | 52.24 Thousand USD | -47.78% |
| 2021 Q1 | 238.58 Thousand USD | 49.89% |
| 2021 Q2 | 97.72 Thousand USD | -59.04% |
| 2020 Q2 | 402.99 Thousand USD | -10.51% |
| 2020 FY | 159.17 Thousand USD | -16.46% |
| 2020 Q1 | 450.31 Thousand USD | 136.33% |
| 2020 Q3 | 224.56 Thousand USD | -44.28% |
| 2020 Q4 | 159.17 Thousand USD | -29.12% |
| 2019 Q4 | 190.54 Thousand USD | -14.15% |
| 2019 Q1 | 51.96 Thousand USD | 14.82% |
| 2019 Q2 | 95.15 Thousand USD | 83.1% |
| 2019 FY | 190.54 Thousand USD | 321.0% |
| 2019 Q3 | 221.94 Thousand USD | 133.26% |
| 2018 Q3 | 162.68 Thousand USD | -56.77% |
| 2018 Q1 | 532.3 Thousand USD | 81.22% |
| 2018 FY | 45.25 Thousand USD | -84.59% |
| 2018 Q4 | 45.25 Thousand USD | -72.18% |
| 2018 Q2 | 376.33 Thousand USD | -29.3% |
| 2017 FY | 293.72 Thousand USD | 9.22% |
| 2017 Q1 | 252.46 Thousand USD | -6.12% |
| 2017 Q2 | 378.5 Thousand USD | 49.93% |
| 2017 Q3 | 334.99 Thousand USD | -11.5% |
| 2017 Q4 | 293.72 Thousand USD | -12.32% |
| 2016 Q1 | 44.75 Thousand USD | -3.89% |
| 2016 FY | 268.92 Thousand USD | 477.54% |
| 2016 Q4 | 268.92 Thousand USD | 61.47% |
| 2016 Q3 | 166.55 Thousand USD | 248.02% |
| 2016 Q2 | 47.85 Thousand USD | 6.93% |
| 2015 Q2 | 104.88 Thousand USD | 2153.25% |
| 2015 Q1 | 4655.00 USD | 287.59% |
| 2015 Q4 | 46.56 Thousand USD | -20.48% |
| 2015 FY | 46.56 Thousand USD | 3777.1% |
| 2015 Q3 | 58.55 Thousand USD | -44.18% |
| 2014 Q4 | 1201.00 USD | 0.0% |
| 2014 Q3 | 1201.00 USD | -47.12% |
| 2014 Q2 | 2271.00 USD | -57.25% |
| 2014 Q1 | 5312.00 USD | -51.62% |
| 2014 FY | 1201.00 USD | -89.06% |
| 2013 Q4 | 10.97 Thousand USD | -12.72% |
| 2013 FY | 10.97 Thousand USD | -53.51% |
| 2013 Q2 | 18.91 Thousand USD | -19.92% |
| 2013 Q1 | 23.61 Thousand USD | 0.0% |
| 2013 Q3 | 12.57 Thousand USD | -33.48% |
| 2012 Q4 | 23.61 Thousand USD | -21.33% |
| 2012 Q3 | 30.01 Thousand USD | 176470.59% |
| 2012 FY | 23.61 Thousand USD | 138811.76% |
| 2012 Q1 | 17.00 USD | 0.0% |
| 2012 Q2 | 17.00 USD | 0.0% |
| 2011 Q4 | 17.00 USD | 0.0% |
| 2011 FY | 17.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| RetinalGenix Technologies Inc. | 156.00 USD | -29465.385% |